Fulcrum Therapeutics to Participate in Upcoming May Conferences
Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in two upcoming investor conferences in May 2025:
1. The H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York on May 20, 2025
2. The RBC Capital Markets Global Healthcare Conference in New York on May 21, 2025, featuring a fireside chat at 3:35 pm ET
The fireside chat webcast will be available on Fulcrum's investor relations website and will remain accessible for at least 30 days after the presentation.
Fulcrum Therapeutics (NASDAQ: FULC), un'azienda biofarmaceutica in fase clinica specializzata nello sviluppo di piccole molecole per malattie genetiche rare, ha annunciato la sua partecipazione a due prossimi convegni per investitori a maggio 2025:
1. La conferenza H.C. Wainwright BioConnect Investor presso il NASDAQ di New York il 20 maggio 2025
2. La RBC Capital Markets Global Healthcare Conference a New York il 21 maggio 2025, con una tavola rotonda alle 15:35 ET
La trasmissione in diretta della tavola rotonda sarà disponibile sul sito web delle relazioni con gli investitori di Fulcrum e resterà accessibile per almeno 30 giorni dopo la presentazione.
Fulcrum Therapeutics (NASDAQ: FULC), una compañía biofarmacéutica en etapa clínica especializada en el desarrollo de pequeñas moléculas para enfermedades genéticas raras, ha anunciado su participación en dos próximas conferencias para inversores en mayo de 2025:
1. La conferencia H.C. Wainwright BioConnect Investor en NASDAQ, Nueva York, el 20 de mayo de 2025
2. La conferencia RBC Capital Markets Global Healthcare en Nueva York, el 21 de mayo de 2025, con una charla junto a la chimenea a las 3:35 pm ET
La transmisión en vivo de la charla estará disponible en el sitio web de relaciones con inversores de Fulcrum y permanecerá accesible durante al menos 30 días después de la presentación.
Fulcrum Therapeutics (NASDAQ: FULC)은 희귀 유전 질환을 위한 소분자 개발에 특화된 임상 단계 바이오제약 회사로, 2025년 5월에 예정된 두 개의 투자자 컨퍼런스에 참여할 것이라고 발표했습니다:
1. 2025년 5월 20일 뉴욕 NASDAQ에서 열리는 H.C. Wainwright BioConnect 투자자 컨퍼런스
2. 2025년 5월 21일 뉴욕에서 열리는 RBC Capital Markets 글로벌 헬스케어 컨퍼런스, 오후 3시 35분(동부시간) 진행되는 파이어사이드 채팅 포함
파이어사이드 채팅 웹캐스트는 Fulcrum 투자자 관계 웹사이트에서 시청 가능하며, 발표 후 최소 30일간 접근할 수 있습니다.
Fulcrum Therapeutics (NASDAQ : FULC), une société biopharmaceutique en phase clinique spécialisée dans le développement de petites molécules pour les maladies génétiques rares, a annoncé sa participation à deux prochaines conférences pour investisseurs en mai 2025 :
1. La conférence H.C. Wainwright BioConnect Investor au NASDAQ de New York le 20 mai 2025
2. La conférence RBC Capital Markets Global Healthcare à New York le 21 mai 2025, avec une discussion informelle à 15h35 ET
La diffusion en direct de la discussion sera disponible sur le site des relations investisseurs de Fulcrum et restera accessible pendant au moins 30 jours après la présentation.
Fulcrum Therapeutics (NASDAQ: FULC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von kleinen Molekülen für seltene genetische Erkrankungen spezialisiert hat, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im Mai 2025 angekündigt:
1. Die H.C. Wainwright BioConnect Investor Conference am NASDAQ in New York am 20. Mai 2025
2. Die RBC Capital Markets Global Healthcare Conference in New York am 21. Mai 2025, mit einem Fireside-Chat um 15:35 Uhr ET
Der Fireside-Chat-Webcast wird auf der Investor-Relations-Website von Fulcrum verfügbar sein und mindestens 30 Tage nach der Präsentation abrufbar bleiben.
- None.
- None.
CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:
- H.C. Wainwright BioConnect Investor Conference at NASDAQ
May 20, 2025
New York, New York
- RBC Capital Markets Global Healthcare Conference
May 21, 2025
Fireside Chat at 3:35 pm ET, Participation link: HERE
New York, New York
The webcast of the fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentations.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When is Fulcrum Therapeutics (FULC) presenting at the RBC Capital Markets Healthcare Conference in 2025?
Which investor conferences is Fulcrum Therapeutics (FULC) attending in May 2025?
Where can I watch Fulcrum Therapeutics' (FULC) conference presentations?
What is Fulcrum Therapeutics' (FULC) main business focus?
